Your browser doesn't support javascript.
loading
A Phase I Trial of SYK Inhibition with Fostamatinib in the Prevention and Treatment of Chronic Graft-Versus-Host Disease.
Lin, Chenyu; DiCioccio, Rachel A; Haykal, Tarek; McManigle, William C; Li, Zhiguo; Anand, Sarah M; Poe, Jonathan C; Bracken, Sonali J; Jia, Wei; Alyea, Edwin P; Cardones, Adela R; Choi, Taewoong; Gasparetto, Cristina; Grunwald, Michael R; Hennig, Therese; Kang, Yubin; Long, Gwynn D; Lopez, Richard; Martin, Melissa; Minor, Kerry K; Quinones, Victor L Perez; Sung, Anthony D; Wiggins, Kristi; Chao, Nelson J; Horwitz, Mitchell E; Rizzieri, David A; Sarantopoulos, Stefanie.
Affiliation
  • Lin C; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • DiCioccio RA; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Haykal T; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • McManigle WC; Division of Pulmonary and Critical Care, Department of Medicine, Medical University of South Carolina, Charleston, South Carolina.
  • Li Z; Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, North Carolina.
  • Anand SM; Division of Hematology and Oncology, Department of Medicine, University of Michigan, Ann Arbor, Michigan.
  • Poe JC; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Bracken SJ; Division of Rheumatology and Immunology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Jia W; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Alyea EP; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Cardones AR; Division of Dermatology, Department of Internal Medicine, University of Kansas Medical Center, Lawrence, Kansas.
  • Choi T; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Gasparetto C; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Grunwald MR; Department of Hematologic Oncology and Blood Disorders, Levine Cancer Institute, Atrium Health, Charlotte, North Carolina.
  • Hennig T; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Kang Y; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Long GD; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Lopez R; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Martin M; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Minor KK; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Quinones VLP; Duke Eye Center, Durham, North Carolina.
  • Sung AD; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Wiggins K; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Chao NJ; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Horwitz ME; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina.
  • Rizzieri DA; Novant Health Cancer Institute, Charlotte, North Carolina.
  • Sarantopoulos S; Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, North Carolina. Electronic address: stefanie.sarantopoulos@duke.edu.
Transplant Cell Ther ; 29(3): 179.e1-179.e10, 2023 03.
Article in En | MEDLINE | ID: mdl-36577483
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bronchiolitis Obliterans Syndrome / Graft vs Host Disease Limits: Animals / Humans Language: En Journal: Transplant Cell Ther Year: 2023 Document type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Bronchiolitis Obliterans Syndrome / Graft vs Host Disease Limits: Animals / Humans Language: En Journal: Transplant Cell Ther Year: 2023 Document type: Article